US EditionPublished • loading... • Updated
PRM Pharma Launches First FDA-Approved 12.5 mg Chlorthalidone for Hypertension
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
PRM Pharma Launches First FDA-Approved 12.5 mg Chlorthalidone for Hypertension
WEST CONSHOHOCKEN, PA — PRM Pharma, LLC announced the nationwide launch of HemiClor® (chlorthalidone) 12.5 mg tablets, the first and only FDA-approved 12.5 mg formulation of chlorthalidone for adult hypertension. The product arrives as new national guidelines reaffirm chlorthalidone’s role as a cornerstone treatment for high blood pressure. The announcement follows the release of the 2025 American Heart Association/American College of Cardiology…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
